bluebird bio, Inc. (BLUE) Reaches $168.45 After 9.00% Up Move; Abercrombie & Fitch Company (ANF) Shorts Increased By 0.54%

April 26, 2018 - By Adrian Erickson

bluebird bio, Inc. (NASDAQ:BLUE) Logo

The stock of bluebird bio, Inc. (NASDAQ:BLUE) is a huge mover today! The stock increased 3.60% or $5.85 during the last trading session, reaching $168.45. About 142,386 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 86.28% since April 26, 2017 and is uptrending. It has outperformed by 74.73% the S&P500.The move comes after 6 months positive chart setup for the $8.42B company. It was reported on Apr, 26 by Barchart.com. We have $183.61 PT which if reached, will make NASDAQ:BLUE worth $757.80M more.

Abercrombie & Fitch Company (NYSE:ANF) had an increase of 0.54% in short interest. ANF’s SI was 13.78M shares in April as released by FINRA. Its up 0.54% from 13.71 million shares previously. With 2.43M avg volume, 6 days are for Abercrombie & Fitch Company (NYSE:ANF)’s short sellers to cover ANF’s short positions. The SI to Abercrombie & Fitch Company’s float is 20.39%. The stock increased 4.13% or $1.07 during the last trading session, reaching $26.95. About 1.35 million shares traded. Abercrombie & Fitch Co. (NYSE:ANF) has risen 103.89% since April 26, 2017 and is uptrending. It has outperformed by 92.34% the S&P500.

Among 26 analysts covering bluebird bio (NASDAQ:BLUE), 14 have Buy rating, 2 Sell and 10 Hold. Therefore 54% are positive. bluebird bio has $309.0 highest and $14 lowest target. $184.96’s average target is 9.80% above currents $168.45 stock price. bluebird bio had 92 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, August 2 by BMO Capital Markets. The rating was maintained by Maxim Group on Friday, June 2 with “Buy”. Maxim Group maintained the stock with “Buy” rating in Thursday, December 1 report. Evercore downgraded the shares of BLUE in report on Monday, November 6 to “In-Line” rating. Wells Fargo maintained the stock with “Buy” rating in Tuesday, October 3 report. The rating was initiated by Oppenheimer with “Hold” on Wednesday, December 20. On Wednesday, March 28 the stock rating was maintained by Oppenheimer with “Hold”. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, August 7. Morgan Stanley maintained bluebird bio, Inc. (NASDAQ:BLUE) on Monday, February 26 with “Equal-Weight” rating. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Sell” rating by Cantor Fitzgerald on Monday, July 24.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on May, 2. They expect $-2.00 EPS, down 19.05% or $0.32 from last year’s $-1.68 per share. After $-2.52 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -20.63% EPS growth.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $8.42 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Investors sentiment decreased to 1.51 in Q4 2017. Its down 0.28, from 1.79 in 2017Q3. It fall, as 21 investors sold bluebird bio, Inc. shares while 79 reduced holdings. 71 funds opened positions while 80 raised stakes. 50.71 million shares or 3.40% more from 49.05 million shares in 2017Q3 were reported. Smith Asset Management Limited Partnership accumulated 3,420 shares. Congress Asset Mgmt Com Ma invested in 0.02% or 8,894 shares. Tekla Cap Management Limited Liability Co stated it has 0.32% in bluebird bio, Inc. (NASDAQ:BLUE). Zeke Capital Advsrs Ltd accumulated 0.05% or 2,588 shares. Wellington Gp Limited Liability Partnership reported 2.79M shares. Susquehanna Intl Grp Llp has invested 0.01% in bluebird bio, Inc. (NASDAQ:BLUE). Highland Mgmt Lp has 0.15% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 18,500 shares. Aperio Grp Lc reported 0.01% in bluebird bio, Inc. (NASDAQ:BLUE). Utd Ser Automobile Association has invested 0.01% in bluebird bio, Inc. (NASDAQ:BLUE). Gam Holdings Ag owns 0.18% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 32,100 shares. L S Advisors Incorporated accumulated 4,460 shares. Moreover, Envestnet Asset Mngmt Inc has 0% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 367 shares. Bb&T Ltd has 0.01% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 3,129 shares. Blackrock Incorporated reported 3.83M shares or 0.03% of all its holdings. Sei Invests Commerce has invested 0% in bluebird bio, Inc. (NASDAQ:BLUE).

Since March 8, 2018, it had 0 insider purchases, and 1 insider sale for $474,400 activity. On Thursday, March 8 MARTINEZ ARTHUR C sold $474,400 worth of Abercrombie & Fitch Co. (NYSE:ANF) or 20,000 shares.

Investors sentiment decreased to 1.23 in Q4 2017. Its down 0.01, from 1.24 in 2017Q3. It fall, as 26 investors sold Abercrombie & Fitch Co. shares while 61 reduced holdings. 53 funds opened positions while 54 raised stakes. 69.17 million shares or 4.27% more from 66.34 million shares in 2017Q3 were reported. Virtu Financial Ltd Liability Co reported 0.02% in Abercrombie & Fitch Co. (NYSE:ANF). Bank Of America De has 0% invested in Abercrombie & Fitch Co. (NYSE:ANF). State Of Tennessee Treasury Department reported 0% stake. Commerzbank Aktiengesellschaft Fi holds 0.09% or 417,245 shares. New York-based Secor Cap Advisors L P has invested 0.08% in Abercrombie & Fitch Co. (NYSE:ANF). Tci Wealth Advisors Inc reported 112 shares stake. Teacher Retirement Systems Of Texas reported 23,405 shares. Millennium Management Limited Liability holds 0.03% or 1.12 million shares. Invesco Limited reported 164,770 shares. Tudor Investment Corporation Et Al stated it has 30,334 shares or 0.01% of all its holdings. Thrivent Fincl For Lutherans has 0% invested in Abercrombie & Fitch Co. (NYSE:ANF). Ameriprise stated it has 345,474 shares. Morgan Stanley has invested 0.01% in Abercrombie & Fitch Co. (NYSE:ANF). Dekabank Deutsche Girozentrale stated it has 380,000 shares or 0.03% of all its holdings. Ajo Ltd Partnership has 0.03% invested in Abercrombie & Fitch Co. (NYSE:ANF).

Abercrombie & Fitch Co. (NYSE:ANF) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>